Anticonvulsants
PreclinicalSmall molecule
Anticonvulsants is one of 12 small molecule programs targeting Alcohol Withdrawal. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Alcohol Withdrawal
#DrugCompanyPhaseTrials
1Lioresal
NovartisApproved
Xyrem
Jazz PharmaceuticalsApproved
Ativan
BBausch Health Americas, Inc.
Approved
Minipress
PfizerApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ketalar
AAultman Health Foundation
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Pitocin
RRetrophin
Approved
Serax
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Luminal
Sun Pharmaceutical Industries, Inc.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anticonvulsants. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details